533902-29-3
533902-29-3 結(jié)構(gòu)式
ANXA2抑制劑多肽價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2022/09/18 | HY-P2333 | ANXA2抑制劑多肽 LCKLSL | 533902-29-3 | 5mg | 2500元 |
| 2022/09/18 | HY-P2333 | ANXA2抑制劑多肽 LCKLSL | 533902-29-3 | 10mg | 4500元 |
| 2022/09/18 | HY-P2333 | ANXA2抑制劑多肽 LCKLSL | 533902-29-3 | 25mg | 8500元 |
常見問題列表
生物活性
LCKLSL 是一種 N 末端六肽，是一種競(jìng)爭(zhēng)性的膜聯(lián)蛋白 A2 (AnxA2) 抑制劑，可有效抑制組織纖溶酶原激活物 (tPA) 與 AnxA2 的結(jié)合。LCKLSL 還可抑制纖溶酶的產(chǎn)生，并具有抗血管生成的作用。靶點(diǎn)
Annexin A2 (AnxA2)
體外研究
In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions.
體內(nèi)研究
Application of LCKLSL in two in vivo models (in chicken chorioallantoic membrane and murine Matrigel plug assays) of angiogenesis demonstrates suppression of the angiogenic responses. Treatment with the LCKLSL peptide significantly decreases the vascular length. At a dose of 5 μg/mL, the LCKLSL peptide significantly decreases the number of vascular branches, junctions and end-points.